Search
basiliximab (Simulect)
Indications:
- prevention of organ transplant rejection
- kidney transplant
- heart transplant
- lung transplant [3]
Dosage:
- 10-20 mg IV (twice)
- intravenous infusion over 20-30 minutes
- given in 2 doses
a) 1st dose 2 hours prior to transpant surgery
b) 2nd dose 4 days after surgery
Adverse effects:
- risk of hypersensitivity (limit to 2 doses)
Mechanism of action:
- mouse-human monoclonal antibody to CD25 (IL2 receptor alpha)
Notes:
- Novartis, FDA-approved 1998
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
General
pharmaceutical monoclonal antibody
immunosuppressive agent
References
- MedicineNet.com
http://www.medicinenet.com/basiliximab-injection/article.htm
- RxList
http://www.rxlist.com/simulect-drug.htm
- Deprecated Reference